医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Launch of a new Protein A Chromatography Resin for purification of Antibody Drugs

2012年10月08日 PM03:00
このエントリーをはてなブックマークに追加


 

OSAKA, Japan

Kaneka Corporation on 19/09/2012 (Osaka, Japan, President: Kimikazu Sugawara) announces the launch of KANEKA KanCapA, a new Protein A Chromatography Resin for the purification of therapeutic antibodies. “KANEKA KanCapA” exhibits high antibody adsorbing capacity and alkaline resistance.

Therapeutic antibodies represent an innovative class of drugs used to treat a wide range of diseases such as rheumatoid arthritis and cancer. Protein A chromatography resin is widely used in the production of therapeutic antibodies due to its high affinity and excellent selectivity for antibodies. Utilizing our expertise in protein design and genetic engineering, we have made significant improvements to ‘Wild type’ or “Native’ Protein A ligand. Immobilization of our improved Protein A ligand to highly cross-linked cellulose beads allows KANEKA KanCapA to exhibit alkaline resistance, stability over repeated cycle use, and to be used at high flow rates from laboratory to industrial scale with high binding capacity.

As a result of positive feedback and evaluation results from our customers we are pleased to announce the commercialization and sales of KANEKA KanCapA in October 2012. We will introduce KANEKA KanCapA at BioProcess International (Oct. 8th – 12th, Providence RI, USA) and at CPhI Worldwide (Oct. 9th-11th, Madrid, Spain). Our expectation is that the excellent properties of KANEKA KanCapA will allow customers to develop stable, streamlined and cost effective antibody purification processes.

In addition we are investing our research and technology resources towards the development of the next generation chromatography resins having the high quality and novel performance for the production of biopharmaceuticals. Along with our group companies, Eurogentec S.A. (Liege, Belgium) for contract manufacturing of biopharmaceuticals and GeneFrontier Corporation (Chiba, Japan) for drug candidate exploration, KANEKA will continue to offer technical and cost effective solutions in the field of biopharmaceuticals.

CONTACT

Dirk Hoegaerts, Ph.D.
Manager, Business Development
Kaneka
Pharma Europe
Tel: +32 (0)2-663-0340
Email: bioproducts@kaneka.be

同じカテゴリーの記事 

  • La Jolla Institute for Immunology and RevolKa started a Research Collaboration
  • U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
  • ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
  • Renesas’ New FemtoClock™ 3 Timing Solution Delivers Industry’s Lowest Power and Leading Jitter Performance of 25fs-rms
  • 成人向け予防接種プログラムは初期投資の19倍もの社会経済的価値をもたらすとの新レポートを発表